U.S. FDA approves Travere Therapeutics' kidney disorder drug
17/02/2023 21:09
Feb 17 xx(Reuters) - Travere Therapeutics TVTX.O said on Friday the U.S. health regulator has granted accelerated approval to its drug to treat a type of chronic kidney disease. (Reporting by Sriparna Roy, Khushi Mandowara and Nandhini Srinivasan in Bengaluru; Editing by Krishna Chandra Eluri) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations